Current status of biomarkers in head and neck cancer
Article first published online: 20 MAY 2008
Copyright © 2008 Wiley-Liss, Inc.
Journal of Surgical Oncology
Special Issue: Seminars in Surgical Oncology: Head and Neck Surgery
Volume 97, Issue 8, pages 640–643, 15 June 2008
How to Cite
Chang, S. S. and Califano, J. (2008), Current status of biomarkers in head and neck cancer. J. Surg. Oncol., 97: 640–643. doi: 10.1002/jso.21023
- Issue published online: 20 MAY 2008
- Article first published online: 20 MAY 2008
- Manuscript Accepted: 12 FEB 2008
- Manuscript Received: 6 FEB 2008
- squamous cell carcinoma
As our understanding of HNSCC increases so has biomarker development. HPV16 integration is a significant marker of favorable prognosis and response to therapy for HNSCC. EGFR-amplification and overexpression is a poor-prognostic indicator. For premalignant lesions, LOH of 3p&9p21 loci confers an elevated risk of malignant transformation. As molecular targets are identified, these will be candidates for biomarkers for detection, diagnosis, prognosis, and therapy. Validation of these biomarkers requires demonstration of independence of significance beyond known biomarkers. J. Surg. Oncol. 2008;97:640–643. © 2008 Wiley-Liss, Inc.